| pubmed-article:17459508 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17459508 | lifeskim:mentions | umls-concept:C0085243 | lld:lifeskim |
| pubmed-article:17459508 | lifeskim:mentions | umls-concept:C0011854 | lld:lifeskim |
| pubmed-article:17459508 | lifeskim:mentions | umls-concept:C0039194 | lld:lifeskim |
| pubmed-article:17459508 | lifeskim:mentions | umls-concept:C0021641 | lld:lifeskim |
| pubmed-article:17459508 | lifeskim:mentions | umls-concept:C0003320 | lld:lifeskim |
| pubmed-article:17459508 | lifeskim:mentions | umls-concept:C1521721 | lld:lifeskim |
| pubmed-article:17459508 | lifeskim:mentions | umls-concept:C0332120 | lld:lifeskim |
| pubmed-article:17459508 | pubmed:dateCreated | 2007-8-13 | lld:pubmed |
| pubmed-article:17459508 | pubmed:abstractText | Rodents have two functional preproinsulin genes named insulin 1 and insulin 2 on different chromosome and have two amino acid differences in insulin B chain. We have established insulin 1 or insulin 2 knockout (KO) non-obese diabetic (NOD) colonies in the animal institute of Kobe University and evaluated anti-insulin autoimmunity. Similar to the previous report, insulin 1-KO provides strong protection from insulitis (islet-infiltration of mononuclear cells) and diabetes, whereas the insulin 2-KO markedly accelerated insulitis and development of diabetes even at further backcross breeding with NOD/Shi/Kbe mice (P<0.0001). Expression of serum anti-insulin autoantibodies (IAA) was enhanced in insulin 2-KO mice at a time between 10 and 15 weeks of age (P<0.005) while the expression of insulin 1-KO NOD mice was rather reduced. Furthermore, T cell reactivity in splenocytes of insulin 2-KO NOD mice to insulin 1 B:9-23 peptide was increased (P<0.05), suggesting that expanding insulin-reactive T cells may contribute to the acceleration of diabetes in insulin 2-KO mice. Based on those observations, we hypothesize that insulin 1 is a crucial T cell antigen in murine autoimmune diabetes and modification of anti-insulin autoimmunity can be applicable to antigen-based therapy for human type 1 diabetic patients. | lld:pubmed |
| pubmed-article:17459508 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17459508 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17459508 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17459508 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17459508 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17459508 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17459508 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:17459508 | pubmed:issn | 0168-8227 | lld:pubmed |
| pubmed-article:17459508 | pubmed:author | pubmed-author:AraiTakashiT | lld:pubmed |
| pubmed-article:17459508 | pubmed:author | pubmed-author:HaraKentaK | lld:pubmed |
| pubmed-article:17459508 | pubmed:author | pubmed-author:YamadaKatsumi... | lld:pubmed |
| pubmed-article:17459508 | pubmed:author | pubmed-author:MoriyamaHiroa... | lld:pubmed |
| pubmed-article:17459508 | pubmed:author | pubmed-author:NagataMasaoM | lld:pubmed |
| pubmed-article:17459508 | pubmed:author | pubmed-author:YasudaHisafum... | lld:pubmed |
| pubmed-article:17459508 | pubmed:author | pubmed-author:KotaniReikoR | lld:pubmed |
| pubmed-article:17459508 | pubmed:author | pubmed-author:OkumachiYasuy... | lld:pubmed |
| pubmed-article:17459508 | pubmed:author | pubmed-author:YokonoKoichK | lld:pubmed |
| pubmed-article:17459508 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:17459508 | pubmed:volume | 77 Suppl 1 | lld:pubmed |
| pubmed-article:17459508 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17459508 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17459508 | pubmed:pagination | S155-60 | lld:pubmed |
| pubmed-article:17459508 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:17459508 | pubmed:meshHeading | pubmed-meshheading:17459508... | lld:pubmed |
| pubmed-article:17459508 | pubmed:meshHeading | pubmed-meshheading:17459508... | lld:pubmed |
| pubmed-article:17459508 | pubmed:meshHeading | pubmed-meshheading:17459508... | lld:pubmed |
| pubmed-article:17459508 | pubmed:meshHeading | pubmed-meshheading:17459508... | lld:pubmed |
| pubmed-article:17459508 | pubmed:meshHeading | pubmed-meshheading:17459508... | lld:pubmed |
| pubmed-article:17459508 | pubmed:meshHeading | pubmed-meshheading:17459508... | lld:pubmed |
| pubmed-article:17459508 | pubmed:meshHeading | pubmed-meshheading:17459508... | lld:pubmed |
| pubmed-article:17459508 | pubmed:meshHeading | pubmed-meshheading:17459508... | lld:pubmed |
| pubmed-article:17459508 | pubmed:meshHeading | pubmed-meshheading:17459508... | lld:pubmed |
| pubmed-article:17459508 | pubmed:meshHeading | pubmed-meshheading:17459508... | lld:pubmed |
| pubmed-article:17459508 | pubmed:year | 2007 | lld:pubmed |
| pubmed-article:17459508 | pubmed:articleTitle | Insulin as a T cell antigen in type 1 diabetes supported by the evidence from the insulin knockout NOD mice. | lld:pubmed |
| pubmed-article:17459508 | pubmed:affiliation | Department of Internal and Geriatric Medicine, Kobe University Graduate School of Medicine, Kobe 650-0017, Japan. hirom@med.kobe-u.ac.jp | lld:pubmed |
| pubmed-article:17459508 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17459508 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| entrez-gene:16333 | entrezgene:pubmed | pubmed-article:17459508 | lld:entrezgene |
| entrez-gene:16334 | entrezgene:pubmed | pubmed-article:17459508 | lld:entrezgene |
